{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:52:51Z","timestamp":1793407971711,"version":"4.5.0"},"reference-count":55,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Sickle cell disease (SCD) is a genetically and clinically heterogeneous disorder marked by hemolysis and vaso-occlusion, leading to a wide range of acute and chronic complications. While newborn screening enables early identification, the optimal timing for initiating disease-modifying therapies (DMTs) remains a critical and evolving question. This review explores how genetic and clinical risk factors, along with phenotypic variability, influence treatment timing, emphasizing a shift toward earlier and more personalized interventions. Hydroxyurea, the most widely used DMT, demonstrates strong evidence for early initiation in severe genotypes yet is underutilized due to concerns around long-term effects and adherence challenges. Additional therapies, such as L-glutamine, crizanlizumab, and formerly voxelotor, highlight the growing yet complex therapeutic landscape. Curative and transformative options, such as hematopoietic stem cell transplantation and newly approved gene therapies, underscore the need for individualized decision-making based on risk, disease trajectory, and patient goals. Rethinking treatment paradigms to incorporate multiagent approaches, biomarker-driven strategies, and earlier intervention may yield improved outcomes. Ultimately, optimizing the timing of therapy initiation requires moving from reactive to proactive care models that consider risk, clinical severity, and evolving therapeutic options, with the goal of improving quality of life and long-term survival for individuals living with SCD.<\/jats:p>","DOI":"10.1182\/hematology.2025000752","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T14:09:59Z","timestamp":1764943799000},"page":"577-584","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Optimizing the right time to start sickle cell therapies"],"prefix":"10.1182","volume":"2025","author":[{"given":"Olufunke Y.","family":"Martin","sequence":"first","affiliation":[{"name":"1 University of Texas Southwestern Medical Center, Division of Pediatric Hematology-Oncology, Children's Medical Center, Center for Cancer and Blood Disorders, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seethal A.","family":"Jacob","sequence":"additional","affiliation":[{"name":"2 Division of Pediatric Hematology, Oncology, and Stem Cell Transplant, Riley Children's Health, Indianapolis, IN"},{"name":"3 Division of Children's Health Services Research, Indiana University School of Medicine, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"issue":"1","key":"2025120616345999100_hem2025000752C1","doi-asserted-by":"crossref","first-page":"18010","DOI":"10.1038\/nrdp.2018.10","article-title":"Sickle cell disease","volume":"4","author":"Kato","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"8","key":"2025120616345999100_hem2025000752C2","doi-asserted-by":"crossref","first-page":"e585","DOI":"10.1016\/S2352-3026(23)00118-7","article-title":"Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000\u20132021: a systematic analysis from the Global Burden of Disease Study 2021","volume":"10","author":"Thomson","year":"2023","journal-title":"Lancet Haematol"},{"issue":"1","key":"2025120616345999100_hem2025000752C3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/ajh.24235","article-title":"Evolution of sickle cell disease from a life- threatening disease of children to a chronic disease of adults: the last 40\u2009years","volume":"91","author":"Chaturvedi","year":"2016","journal-title":"Am J Hematol"},{"issue":"6","key":"2025120616345999100_hem2025000752C4","doi-asserted-by":"crossref","first-page":"e2024067341","DOI":"10.1542\/peds.2024-067341","article-title":"Trends in sickle cell disease mortality: 1979-2020","volume":"154","author":"Karkoska","year":"2024","journal-title":"Pediatrics"},{"issue":"2","key":"2025120616345999100_hem2025000752C5","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1182\/blood.V86.2.776.bloodjournal862776","article-title":"Clinical events in the first decade in a cohort of infants with sickle cell disease: Cooperative study of sickle cell disease","volume":"86","author":"Gill","year":"1995","journal-title":"Blood"},{"issue":"7020","key":"2025120616345999100_hem2025000752C6","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1136\/bmj.311.7020.1600","article-title":"Improved survival in homozygous sickle cell disease: lessons from a cohort study","volume":"311","author":"Lee","year":"1995","journal-title":"BMJ"},{"issue":"6","key":"2025120616345999100_hem2025000752C7","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1177\/0033354919881438","article-title":"Reducing health care disparities in sickle cell disease: a review","volume":"134","author":"Lee","year":"2019","journal-title":"Public Health Rep"},{"issue":"suppl 5, pt 11","key":"2025120616345999100_hem2025000752C8","first-page":"S12","article-title":"A multimodal approach to managing the symptoms of multiple sclerosis","volume":"63","author":"Crayton","year":"2004","journal-title":"Neurology"},{"issue":"8","key":"2025120616345999100_hem2025000752C9","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S2213-2600(16)00023-0","article-title":"Progress in therapies for cystic fibrosis","volume":"4","author":"De Boeck","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"1","key":"2025120616345999100_hem2025000752C10","doi-asserted-by":"crossref","first-page":"3470654","DOI":"10.1155\/2024\/3470654","article-title":"Treating type 2 diabetes with early, intensive, multimodal pharmacotherapy: real-world evidence from an international collaborative database","volume":"2024","author":"Anson","year":"2024","journal-title":"J Diab Res"},{"issue":"2","key":"2025120616345999100_hem2025000752C11","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1365-2141.2011.08916.x","article-title":"Fetal haemoglobin levels and haematological characteristics of compound heterozygotes for haemoglobin S and deletional hereditary persistence of fetal haemoglobin","volume":"156","author":"Ngo","year":"2012","journal-title":"Br J Haematol"},{"issue":"5","key":"2025120616345999100_hem2025000752C12","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1182\/blood.V68.5.985.985","article-title":"Alpha-thalassemia in blacks: genetic and clinical aspects and interactions with the sickle hemoglobin gene","volume":"68","author":"Steinberg","year":"1986","journal-title":"Blood"},{"key":"2025120616345999100_hem2025000752C13","first-page":"29","article-title":"Sickle cell anemia: HBB haplotypes; clinical heterogeneity; iPSC modeling","volume-title":"Recent Advances in iPSC Disease Modeling","author":"Vanuytsel","year":"2020"},{"issue":"1","key":"2025120616345999100_hem2025000752C14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/hematology.2024000678","article-title":"Sickle cell disease in India: the journey and hope for the future","volume":"2024","author":"Gupta","year":"2024","journal-title":"Hematology"},{"issue":"8","key":"2025120616345999100_hem2025000752C15","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/ajh.23232","article-title":"Genetic modifiers of sickle cell disease","volume":"87","author":"Steinberg","year":"2012","journal-title":"Am J Hematol"},{"issue":"9","key":"2025120616345999100_hem2025000752C16","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1002\/ajh.23777","article-title":"Reticulocytosis and anemia are associated with an increased risk of death and stroke in the newborn cohort of the Cooperative Study of Sickle Cell Disease","volume":"89","author":"Meier","year":"2014","journal-title":"Am J Hematol"},{"key":"2025120616345999100_hem2025000752C17","doi-asserted-by":"publisher","DOI":"10.31478\/202309b","article-title":"Primary, secondary, and tertiary prevention of substance use disorder through sociological strategies","volume":"2023","author":"Latimore","year":"2023","journal-title":"NAM Perspect"},{"issue":"9","key":"2025120616345999100_hem2025000752C18","doi-asserted-by":"crossref","first-page":"e27228","DOI":"10.1002\/pbc.27228","article-title":"Sickle cell clinical research and intervention program (SCCRIP): a lifespan cohort study for sickle cell disease progression from the pediatric stage into adulthood","volume":"65","author":"Hankins","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"2025120616345999100_hem2025000752C19","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1056\/NEJM200001133420203","article-title":"Prediction of adverse outcomes in children with sickle cell disease","volume":"342","author":"Miller","year":"2000","journal-title":"N Engl J Med"},{"issue":"20","key":"2025120616345999100_hem2025000752C20","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia","volume":"332","author":"Charache","year":"1995","journal-title":"N Engl J Med"},{"issue":"5","key":"2025120616345999100_hem2025000752C21","first-page":"1550","article-title":"Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I\/II trial","volume":"94","author":"Kinney","year":"1999","journal-title":"Blood"},{"issue":"9778","key":"2025120616345999100_hem2025000752C22","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/S0140-6736(11)60355-3","article-title":"Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)","volume":"377","author":"Wang","year":"2011","journal-title":"Lancet"},{"issue":"1","key":"2025120616345999100_hem2025000752C23","doi-asserted-by":"crossref","first-page":"100001","DOI":"10.1016\/j.bglo.2025.100001","article-title":"Hydroxyurea to decrease stroke risk in children with sickle cell anemia: a systematic review and meta-analysis","volume":"1","author":"Ambrose","year":"2025","journal-title":"Blood Global Hematol"},{"issue":"3","key":"2025120616345999100_hem2025000752C24","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/bjh.17663","article-title":"Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia","volume":"194","author":"Quinn","year":"2021","journal-title":"Br J Haematol"},{"issue":"11","key":"2025120616345999100_hem2025000752C25","doi-asserted-by":"crossref","first-page":"e050880","DOI":"10.1136\/bmjopen-2021-050880","article-title":"Identifying barriers to evidence-based care for sickle cell disease: results from the Sickle Cell Disease Implementation Consortium cross-sectional survey of healthcare providers in the USA","volume":"11","author":"Smeltzer","year":"2021","journal-title":"BMJ Open"},{"issue":"1","key":"2025120616345999100_hem2025000752C26","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1056\/NEJM199807023390102","article-title":"Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography","volume":"339","author":"Adams","year":"1998","journal-title":"N Engl J Med"},{"issue":"10019","key":"2025120616345999100_hem2025000752C27","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0140-6736(15)01041-7","article-title":"Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia\u2014TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial","volume":"387","author":"Ware","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"2025120616345999100_hem2025000752C28","article-title":"Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease","volume":"1","author":"Estcourt","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"26","key":"2025120616345999100_hem2025000752C29","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1056\/NEJMoa050460","article-title":"Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease","volume":"353","author":"Adams","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"2025120616345999100_hem2025000752C30","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1182\/hematology.2021000307","article-title":"Indications for transfusion in the management of sickle cell disease","volume":"2021","author":"Han","year":"2021","journal-title":"Hematology"},{"issue":"6","key":"2025120616345999100_hem2025000752C31","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1067\/mpd.2001.119593","article-title":"Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia","volume":"139","author":"Miller","year":"2001","journal-title":"J Pediatr"},{"issue":"2","key":"2025120616345999100_hem2025000752C32","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/bjh.14383","article-title":"Guidelines on red cell transfusion in sickle cell disease part II: indications for transfusion","volume":"176","author":"Davis","year":"2017","journal-title":"Br J Haematol"},{"key":"2025120616345999100_hem2025000752C33","first-page":"4","article-title":"L-glutamine therapy reduces endothelial adhesion of sickle red blood cells to human umbilical vein endothelial cells","volume":"5","author":"Niihara","year":"2005","journal-title":"BMC Blood Disord"},{"issue":"19","key":"2025120616345999100_hem2025000752C34","first-page":"1880","article-title":"A phase 3 trial of l-glutamine in sickle cell disease","volume":"379","author":"Niihara","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"2025120616345999100_hem2025000752C35","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1089\/ped.2017.0814","article-title":"Acute chest syndrome in children with sickle cell disease","volume":"30","author":"Jain","year":"2017","journal-title":"Pediatr Allergy Immunol Pulmonol"},{"key":"2025120616345999100_hem2025000752C36","doi-asserted-by":"crossref","first-page":"931925","DOI":"10.3389\/fmed.2022.931925","article-title":"Real-world data on efficacy of L-glutamine in preventing sickle cell disease-related complications in pediatric and adult patients","volume":"9","author":"Elenga","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"7","key":"2025120616345999100_hem2025000752C37","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1182\/blood-2015-09-618538","article-title":"Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology","volume":"127","author":"Zhang","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2025120616345999100_hem2025000752C38","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease","volume":"376","author":"Ataga","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"2025120616345999100_hem2025000752C39","doi-asserted-by":"crossref","first-page":"e248","DOI":"10.1016\/S2352-3026(24)00384-3","article-title":"Crizanlizumab with or without hydroxyurea in patients with sickle cell disease (STAND): primary analyses from a placebo-controlled, randomised, double-blind, phase 3 trial","volume":"12","author":"Abboud","year":"2025","journal-title":"Lancet Haematol"},{"issue":"suppl 1","key":"2025120616345999100_hem2025000752C40","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1182\/blood-2021-149849","article-title":"A phase II, randomized, multicenter, open-label study evaluating the effect of crizanlizumab and standard of care (SoC) versus standard of care alone on renal function in patients with chronic kidney disease due to sickle cell nephropathy (STEADFAST)","volume":"138","author":"Saraf","year":"2021","journal-title":"Blood"},{"issue":"15","key":"2025120616345999100_hem2025000752C41","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1182\/blood.2020006020","article-title":"Evaluation of longitudinal pain study in sickle cell disease (ELIPSIS) by patient-reported outcomes, actigraphy, and biomarkers","volume":"137","author":"Pittman","year":"2021","journal-title":"Blood"},{"issue":"6","key":"2025120616345999100_hem2025000752C42","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/bjh.17643","article-title":"Flow adhesion of whole blood to P-selectin: a prognostic biomarker for vaso-occlusive crisis in sickle cell disease","volume":"194","author":"Hines","year":"2021","journal-title":"Br J Haematol"},{"issue":"4","key":"2025120616345999100_hem2025000752C43","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/bjh.17954","article-title":"Longitudinal assessment of adhesion to vascular cell adhesion molecule-1 at steady state and during vaso- occlusive crises in sickle cell disease","volume":"196","author":"White","year":"2022","journal-title":"Br J Haematol"},{"issue":"11","key":"2025120616345999100_hem2025000752C44","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2016-10-745711","article-title":"Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation","volume":"129","author":"Gluckman","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2025120616345999100_hem2025000752C45","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1053\/j.seminhematol.2018.04.011","article-title":"Curative therapies: allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease","volume":"55","author":"Guilcher","year":"2018","journal-title":"Semin Hematol"},{"issue":"5","key":"2025120616345999100_hem2025000752C46","doi-asserted-by":"crossref","first-page":"103554","DOI":"10.1016\/j.transci.2022.103554","article-title":"Umbilical cord blood as a hematopoietic stem cell source in transplantation for pediatric sickle cell disease: current challenges and strategies","volume":"61","author":"Malhotra","year":"2022","journal-title":"Transfus Apher Sci"},{"issue":"11","key":"2025120616345999100_hem2025000752C47","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1080\/17474086.2023.2268271","article-title":"Outcomes and long-term effects of hematopoietic stem cell transplant in sickle cell disease","volume":"16","author":"Inam","year":"2023","journal-title":"Expert Rev Hematol"},{"key":"2025120616345999100_hem2025000752C48","doi-asserted-by":"crossref","first-page":"551170","DOI":"10.3389\/fped.2020.551170","article-title":"Hematopoietic cell transplantation for sickle cell disease","volume":"8","author":"Krishnamurti","year":"2020","journal-title":"Front Pediatr"},{"issue":"suppl 4, pt 6","key":"2025120616345999100_hem2025000752C49","doi-asserted-by":"crossref","first-page":"S398","DOI":"10.1016\/j.amepre.2011.09.013","article-title":"Sickle cell disease in Africa: a neglected cause of early childhood mortality","volume":"41","author":"Grosse","year":"2011","journal-title":"Am J Prev Med"},{"issue":"1","key":"2025120616345999100_hem2025000752C50","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1182\/blood-2023-174229","article-title":"Efficacy, safety, and health- related quality of life (HRQOL) in patients with sickle cell disease (SCD) who have received lovotibeglogene autotemcel (lovo-cel) gene therapy: up to 60 months of follow-up","volume":"142","author":"Kanter","year":"2023","journal-title":"Blood"},{"issue":"18","key":"2025120616345999100_hem2025000752C51","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene autotemcel for severe sickle cell disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"N Engl J Med"},{"key":"2025120616345999100_hem2025000752C52","article-title":"Examining variation in gene therapy access across states","volume-title":"Avalere Health Advisory","author":"Kruger","year":"2024"},{"issue":"9","key":"2025120616345999100_hem2025000752C53","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1016\/j.ymthe.2022.08.009","article-title":"Assessing the state of Medicaid coverage for gene and cell therapies","volume":"30","author":"Berry","year":"2022","journal-title":"Mol Ther"},{"issue":"11","key":"2025120616345999100_hem2025000752C54","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1182\/blood.2019003776","article-title":"Gene therapy for sickle cell disease: moving from the bench to the bedside","volume":"138","author":"Abraham","year":"2021","journal-title":"Blood"},{"key":"2025120616345999100_hem2025000752C55","doi-asserted-by":"crossref","first-page":"100121","DOI":"10.1016\/j.bvth.2025.100121","article-title":"Acute pain in pediatric sickle cell patients without chronic pain shows elevated VCAM-1 and P-Selectin adhesion","author":"Martin","year":"2025","journal-title":"Blood Vessel Thromb Hemost"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/577\/2470400\/577martin.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/577\/2470400\/577martin.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T21:35:06Z","timestamp":1765056906000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2025\/1\/577\/556890\/Optimizing-the-right-time-to-start-sickle-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,5]]},"published-print":{"date-parts":[[2025,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2025000752","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,5]]},"published":{"date-parts":[[2025,12,5]]}}}